📣 VC round data is live. Check it out!

Yifan Pharmaceutical Valuation Multiples

Discover Yifan Pharmaceutical's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Intellia Therapeutics, Iovance Biotherapeutics, Bausch Health, Jinyu Bio-Technology Co. and more.

Yifan Pharmaceutical Overview

About Yifan Pharmaceutical

Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.


Founded

1994

HQ

China

Employees

1.5K

Financials (LTM)

Revenue: $785M
EBITDA: $139M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Yifan Pharmaceutical Financials

Yifan Pharmaceutical reported last 12-month revenue of $785M and EBITDA of $139M.

In the same LTM period, Yifan Pharmaceutical generated $371M in gross profit, $139M in EBITDA, and $64M in net income.

Revenue (LTM)


Yifan Pharmaceutical P&L

In the most recent fiscal year, Yifan Pharmaceutical reported revenue of $759M and EBITDA of $129M.

Yifan Pharmaceutical is profitable as of last fiscal year, with gross margin of 47%, EBITDA margin of 17%, and net margin of 8%.

See analyst estimates for Yifan Pharmaceutical
LTMLast FY202320242025202620272028
Revenue$785M$759M$601M$763M$759M
Gross Profit$371M$356M$288M$362M$356M
Gross Margin47%47%48%47%47%
EBITDA$139M$129M($77M)$117M$122M
EBITDA Margin18%17%(13%)15%16%
EBIT Margin9%11%3%12%11%
Net Profit$64M$59M($81M)$57M$59M
Net Margin8%8%(14%)7%8%
Net Debt-$197M---

Financial data powered by Morningstar, Inc.

Yifan Pharmaceutical Stock Performance

Yifan Pharmaceutical has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Yifan Pharmaceutical's stock price is $1.53.

Yifan Pharmaceutical share price decreased by 1.2% in the last 30 days, and by 19.1% in the last year.

Yifan Pharmaceutical has an EPS (earnings per share) of $0.05.

See more trading valuation data for Yifan Pharmaceutical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-1.6%-1.2%-17.9%-19.1%$0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Yifan Pharmaceutical Valuation Multiples

Yifan Pharmaceutical trades at 2.7x EV/Revenue multiple, and 15.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Yifan Pharmaceutical

EV / Revenue (LTM)


Yifan Pharmaceutical Financial Valuation Multiples

As of June 3, 2026, Yifan Pharmaceutical has market cap of $2B and EV of $2B.

Yifan Pharmaceutical has a P/E ratio of 29.0x.

LTMLast FY202320242025202620272028
EV/Revenue2.7x2.8x3.5x2.7x2.8x
EV/EBITDA15.1x16.3x(27.1x)17.9x17.2x
EV/EBIT28.3x24.6x101.1x23.5x24.6x
EV/Gross Profit5.7x5.9x7.3x5.8x5.9x
P/E29.0x31.3x(22.8x)32.6x31.3x
EV/FCF-(140.7x)(91.2x)n/m(140.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Yifan Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Yifan Pharmaceutical Margins & Growth Rates

Yifan Pharmaceutical grew revenue by 10% and EBITDA by 18% in the last fiscal year.

In the most recent fiscal year, Yifan Pharmaceutical reported gross margin of 47%, EBITDA margin of 17%, and net margin of 8%.

See estimated margins and future growth rates for Yifan Pharmaceutical

Yifan Pharmaceutical Margins

Last FY202420252026202720282029
Gross Margin47%47%47%48%
EBITDA Margin17%15%16%18%
EBIT Margin11%12%11%10%
Net Margin8%7%8%9%
FCF Margin(2%)0%(2%)-

Yifan Pharmaceutical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%27%(1%)10%
Gross Profit Growth11%26%(2%)11%
EBITDA Growth18%(252%)4%25%
EBIT Growth(3%)331%(4%)(3%)
Net Profit Growth20%(170%)4%20%
FCF Growth-(108%)(902%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Yifan Pharmaceutical Operational KPIs

Yifan Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Yifan Pharmaceutical's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Yifan Pharmaceutical's Rule of X is 42% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Yifan Pharmaceutical
LTMLast FY202320242025202620272028
Rule of 4027%28%---
Bessemer Rule of X41%42%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue23%22%22%19%18%
G&A Expenses to Revenue8%8%3%3%3%
R&D Expenses to Revenue6%6%8%6%6%
Opex to Revenue-36%44%36%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Yifan Pharmaceutical Competitors

Yifan Pharmaceutical competitors include Intellia Therapeutics, Iovance Biotherapeutics, Bausch Health, Jinyu Bio-Technology Co., Kalbe Farma, TransThera Sciences, Ocular Therapeutix, Mesoblast, Galapagos and Guobang Pharma.

Most Yifan Pharmaceutical public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Intellia Therapeutics22.7x24.0x(3.7x)(3.7x)
Iovance Biotherapeutics5.9x5.1x(4.5x)(5.0x)
Bausch Health2.1x2.1x6.0x5.8x
Jinyu Bio-Technology Co.8.2x7.6x31.4x31.9x
Kalbe Farma0.8x0.8x5.2x5.4x
TransThera Sciences--(42.3x)-
Ocular Therapeutix23.7x23.7x(4.9x)(3.9x)
Mesoblast110.7x16.5x(27.7x)(68.1x)

This data is available for Pro users. Sign up to see all Yifan Pharmaceutical competitors and their valuation data.

Start Free Trial

Investments by Yifan Pharmaceutical

Yifan Pharmaceutical has invested in 2 companies to date.

Latest investment by Yifan Pharmaceutical was on June 2nd 2022. Yifan Pharmaceutical invested in Evive Biotech in their $70M Undisclosed stage round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Yifan Pharmaceutical

Evive Biotech
Generon (Shanghai) Corporation
Description
Evive Biotech is a biologics developer advancing therapies for oncology and immunology disorders through its DiKine bispecific fusion protein platform and ITab tumor-targeted immunotherapy platform. Shanghai-headquartered with facilities in Singapore and San Francisco, the company maintains an in-house cGMP manufacturing site compliant with FDA, EMA, and NMPA regulations. Its pipeline features ET-01, a Phase 1 anti-EGFR x TGF-β bispecific antibody for hepatocellular carcinoma, and EB-003, an IL-18 fusion protein for inflammatory bowel disease. Established in 2004, Evive Biotech collaborates with global partners to accelerate clinical progression across multiple indications.
Generon (Shanghai) Corporation Ltd. is a Shanghai-headquartered biotech firm manufacturing recombinant proteins for cancer and autoimmune therapies. The company operates R&D in Zhangjiang Hi-Tech Park and cGMP facilities in Beijing, adhering to FDA, EMA, and CFDA standards. Generon advances biosimilars like etanercept and novel Fc-fusion proteins through Phase I trials.
HQ CountrySingaporeChina
HQ City
Singapore
Shanghai
Deal Date2 Jun 20222 Jun 2022
RoundUndisclosed stageUndisclosed stage
Raised$70M$70M
InvestorsSino Biopharmaceutical; Yifan PharmaceuticalSino Biopharmaceutical; Yifan Pharmaceutical
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Yifan Pharmaceutical investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Yifan Pharmaceutical

When was Yifan Pharmaceutical founded?Yifan Pharmaceutical was founded in 1994.
Where is Yifan Pharmaceutical headquartered?Yifan Pharmaceutical is headquartered in China.
How many employees does Yifan Pharmaceutical have?As of today, Yifan Pharmaceutical has over 1K employees.
Is Yifan Pharmaceutical publicly listed?Yes, Yifan Pharmaceutical is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Yifan Pharmaceutical?Yifan Pharmaceutical trades under 002019 ticker.
When did Yifan Pharmaceutical go public?Yifan Pharmaceutical went public in 2004.
Who are competitors of Yifan Pharmaceutical?Yifan Pharmaceutical main competitors include Intellia Therapeutics, Iovance Biotherapeutics, Bausch Health, Jinyu Bio-Technology Co., Kalbe Farma, TransThera Sciences, Ocular Therapeutix, Mesoblast, Galapagos, Guobang Pharma.
What is the current market cap of Yifan Pharmaceutical?Yifan Pharmaceutical's current market cap is $2B.
What is the current revenue of Yifan Pharmaceutical?Yifan Pharmaceutical's last 12 months revenue is $785M.
What is the current revenue growth of Yifan Pharmaceutical?Yifan Pharmaceutical revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of Yifan Pharmaceutical?Current revenue multiple of Yifan Pharmaceutical is 2.7x.
What is the current EBITDA of Yifan Pharmaceutical?Yifan Pharmaceutical's last 12 months EBITDA is $139M.
What is Yifan Pharmaceutical's EBITDA margin?Yifan Pharmaceutical's last 12 months EBITDA margin is 18%.
What is the current EV/EBITDA multiple of Yifan Pharmaceutical?Current EBITDA multiple of Yifan Pharmaceutical is 15.1x.
How many companies Yifan Pharmaceutical has acquired to date?Yifan Pharmaceutical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Yifan Pharmaceutical has invested to date?As of June 2026, Yifan Pharmaceutical has invested in 2 companies.
What was the last Yifan Pharmaceutical investment?On 2nd June 2022 Yifan Pharmaceutical invested in Evive Biotech, participating in a $70M Undisclosed stage round, alongside Sino Biopharmaceutical.
In what companies Yifan Pharmaceutical invested in?Yifan Pharmaceutical invested in Evive Biotech and Generon (Shanghai) Corporation.

See public comps similar to Yifan Pharmaceutical

Lists including Yifan Pharmaceutical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial